Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zhejiang Huahai Pharmaceutical Co., Ltd. Announces FY 2012 H1 Net Profit Outlook


Sunday, 22 Jul 2012 08:00pm EDT 

Zhejiang Huahai Pharmaceutical Co., Ltd. announced that it expects its net profit for the first half of fiscal year (FY) 2012 to increase by 20% to 30%, compared to the net profit of the same period in FY 2011 (RMB 131,699,458.35). The Company cited increased sales of sartan bulk drug as the main reason for the forecast. 

Company Quote

11.43
0.08 +0.70%
11 Jul 2014